Hinova Pharmaceuticals (SH:688302) Sou Hu Cai Jing·2026-01-30 12:10Core Viewpoint - The company, HaiChuang Pharmaceutical, anticipates a net loss of 155 million to 185 million yuan for the year 2025 after deducting non-recurring gains and losses, primarily due to the impact of its first Class 1 new drug, Deuteroenzalutamide soft capsules, which is expected to generate limited revenue in the initial year of sales [1][2]. Group 1: Performance Forecast - The company expects its operating revenue for 2025 to be between 19 million and 22 million yuan, significantly lower than previous expectations due to the inclusion of its product in the National Medical Insurance Catalog, which will lead to a price reduction [2]. - Research and development expenses are projected to be between 105 million and 125 million yuan for 2025, a decrease of approximately 49 million to 69 million yuan compared to the previous year, reflecting a strategic optimization of the R&D pipeline [2]. Group 2: Q3 2025 Financial Results - For the first three quarters of 2025, the company's main revenue reached 23.35 million yuan, a substantial increase of 21,180.28% year-on-year [3]. - The net profit attributable to shareholders for the same period was -99.15 million yuan, showing a year-on-year increase of 35.65% in losses [3]. - The company reported a gross margin of 99.57% and a debt ratio of 19.24%, indicating strong profitability despite the net losses [3].